SOUTH SAN FRANCISCO, Calif.,
Dec. 18, 2019 /PRNewswire/
-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an
oncology-focused precision medicine company committed to the
discovery and development of targeted therapeutics to treat cancer,
announced the appointment of Wendy L.
Yarno as a Director of its Board of Directors.
Ms. Yarno spent 26 years at Merck & Co. in commercial and
human resource positions of increasing seniority, including most
recently as Executive Vice President and Chief Marketing
Officer. She previously served as General Manager,
Cardiovascular / Metabolic U.S. Business Unit and as Executive Vice
President, Worldwide Human Health Marketing. In these roles,
Ms. Yarno developed deep expertise in pharmaceutical
commercialization, including drug development, regulatory strategy,
market development, global product strategy and product life-cycle
management.
Ms. Yarno currently serves on the board of directors of publicly
traded life sciences companies Global Blood Therapeutics, Inovio
Pharmaceuticals, Inc. and Myokardia. She previously served on
the board of directors of various other life science companies,
including Alder Biopharmaceuticals, Durata Therapeutics, St. Jude
Medical and Medivation.
"Wendy brings a unique breadth of experience in pre-and
post-launch commercialization of pharmaceuticals to our Board,"
said John Diekman, Ph.D., Chairman
of IDEAYA's Board of Directors.
Yujiro S. Hata, Chief Executive Officer and President at
IDEAYA Biosciences observed that "Wendy's commercial experience and
leadership will be invaluable to IDEAYA, in particular as we
advance clinical development of our lead clinical development
program, IDE196, into a potentially registration-enabling
single-arm Phase 2 clinical trial in metastatic uveal melanoma,
anticipated in first quarter 2020."
"I'm delighted to join IDEAYA's Board of Directors to help
advance IDEAYA's vision of improving lives through transformative
precision medicines. I am excited to contribute to IDEAYA's
pipeline of precision medicine oncology therapeutics, including
approaches directly targeting oncogenic pathways and synthetic
lethality – an emerging class of precision medicine targets,"
said Ms. Yarno.
About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company committed
to the discovery and development of targeted therapeutics for
patient populations selected using molecular diagnostics.
IDEAYA's approach integrates capabilities in identifying and
validating translational biomarkers with small molecule drug
discovery to select patient populations most likely to benefit from
the targeted therapies IDEAYA is developing. IDEAYA is
applying these capabilities across multiple classes of precision
medicine, including direct targeting of oncogenic pathways and
synthetic lethality – which represents an emerging class of
precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including,
but not limited to, statements related to expected timing for
advancing clinical development of IDE196 into a potentially
registration-enabling single-arm Phase 2 clinical trial in
metastatic uveal melanoma. Such forward-looking statements involve
substantial risks and uncertainties that could cause IDEAYA's
preclinical and clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the drug development process, including IDEAYA's programs' early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, IDEAYA's ability to successfully
establish, protect and defend its intellectual property and other
matters that could affect the sufficiency of existing cash to fund
operations. IDEAYA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of IDEAYA in general, see IDEAYA's
recent Quarterly Report on Form 10-Q filed on November 13, 2019 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-wendy-yarno-to-its-board-of-directors-300976587.html
SOURCE IDEAYA Biosciences, Inc.